| Literature DB >> 33109719 |
Xiao Albert Zhou1, Jiadong Zhou1, Long Zhao2, Guihui Yu1, Jun Zhan3, Chanyi Shi1, Ruoshi Yuan1, Yan Wang4, Changfeng Chen1, Wenjia Zhang1, Donghao Xu5, Yingjiang Ye2, Weibin Wang1, Zhanlong Shen6, Wei Wang7, Jiadong Wang8.
Abstract
Aberrant programmed cell death protein 1 (PD-1) expression on the surface of T cells is known to inhibit T cell effector activity and to play a pivotal role in tumor immune escape; thus, maintaining an appropriate level of PD-1 expression is of great significance. We identified KLHL22, an adaptor of the Cul3-based E3 ligase, as a major PD-1-associated protein that mediates the degradation of PD-1 before its transport to the cell surface. KLHL22 deficiency leads to overaccumulation of PD-1, which represses the antitumor response of T cells and promotes tumor progression. Importantly, KLHL22 was markedly decreased in tumor-infiltrating T cells from colorectal cancer patients. Meanwhile, treatment with 5-fluorouracil (5-FU) could increase PD-1 expression by inhibiting the transcription of KLHL22. These findings reveal that KLHL22 plays a crucial role in preventing excessive T cell suppression by maintaining PD-1 expression homeostasis and suggest the therapeutic potential of 5-FU in combination with anti-PD-1 in colorectal cancer patients.Entities:
Keywords: 5-FU; PD-1; immune checkpoint block therapy; protein degradation
Mesh:
Substances:
Year: 2020 PMID: 33109719 PMCID: PMC7668036 DOI: 10.1073/pnas.2004570117
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205